Blinatumomab
•B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD)
•Relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
•A bispecific CD19-directed CD3 T-cell engager
•Binds to CD19 expressed on the surface of B cells and CD3 expressed on the surface of T cells
•Activates endogenous T cells by connecting CD3 in the T-cell receptor complex with CD19 on benign and malignant B cells
•Upregulation of cell adhesion molecules, production of cytolytic proteins, release of inflamm